TRGV3: A Promising Protein for Drug Development (G6976)

Target Name: TRGV3

NCBI ID: G6976

TRGV3

Other Name(s): TCRGV3 | V1S3 | T cell receptor gamma variable 3

TRGV3: A Promising Protein for Drug Development

TRGV3 (Tissue Response to G protein-Coupled Receptors) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a critical role in cellular signaling.

TRGV3 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is highly conserved across various species, and its sequence is similar to that of other GPCR proteins. TRGV3 is localized to the end of the transmembrane domain of the protein, and it contains a single extracellular domain that is involved in the formation of a complex with G proteins.

The function of TRGV3 is not well understood, but it is thought to play a role in the regulation of cellular signaling pathways. TRGV3 is involved in the signaling cascade of several different signaling pathways, including the regulation of neurotransmitter release, pain perception, and inflammation.

One of the most promising aspects of TRGV3 is its potential as a drug target. TRGV3 is a good candidate for development as a drug because of its unique structure and its involvement in multiple cellular signaling pathways.

TRGV3 can be a useful biomarker for the diagnosis and evaluation of various diseases, including neurodegenerative disorders, pain disorders, and inflammatory diseases. For example, TRGV3 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, and it has been suggested as a potential therapeutic target for this disorder.

In addition to its potential clinical applications, TRGV3 is also a useful tool for the study of GPCR signaling pathways. TRGV3 is a good model for studying the interactions between G proteins and their cognate receptors, and it can be used to study the effects of different G protein regulators on TRGV3 function.

In conclusion, TRGV3 is a unique and promising protein that is involved in the regulation of multiple cellular signaling pathways. Its structure and function make it a good candidate for development as a drug target. Further research is needed to fully understand the role of TRGV3 in cellular signaling and its potential as a therapeutic agent.

Protein Name: T Cell Receptor Gamma Variable 3

Functions: V region of the variable domain of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:23348415, PubMed:28920588). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRGV3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRGV3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets